

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY

**As rescanning documents *will not* correct
images, please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

08/443982

#18
attach

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C12N 15/52, 9/64, C07K 16/40	A1	(11) International Publication Number: WO 97/18313 (43) International Publication Date: 22 May 1997 (22.05.97)
(21) International Application Number: PCT/US96/18118		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GR, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 12 November 1996 (12.11.96)		
(30) Priority Data: 08/556,627 13 November 1995 (13.11.95) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicants: IDUN PHARMACEUTICALS, INC. (US/US); Suite 300, 11085 North Torrey Pines Road, La Jolla, CA 92037 (US). THOMAS JEFFERSON UNIVERSITY (US/US); 1020 Locust Street, Philadelphia, PA 19107-6799 (US).		
(72) Inventors: ALNEMRI, Emad, S.; 805 Meetinghouse Road, Ambler, PA 19002 (US). FERNANDES-ALNEMRI, Teresa; 805 Meetinghouse Road, Ambler, PA 19002 (US). LITWACK, Gerald; 380 Montgomery Avenue, Wynnewood, PA 19096 (US). ARMSTRONG, Robert; 5663 Scripps Street, San Diego, CA 92122 (US). TOMASELLI, Kevin; 539 Westbourne Street, La Jolla, CA 92037 (US).		
(74) Agents: GAY, David, A. et al.; Campbell & Flores LLP., Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).		

(54) Title: MCH3, AN APOPTOTIC PROTEASE, NUCLEIC ACIDS ENCODING AND METHODS OF USE

(57) Abstract

The invention provides an isolated gene encoding Mch3, or functional fragment thereof. Also provided is an isolated nucleic acid sequence encoding Mch3 or functional fragment thereof. The gene or nucleic acid sequence can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch3 nucleotide sequence. An isolated Mch3 polypeptide or functional fragment thereof is also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BR	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
RJ	Russia	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	L1	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LX	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

MCH3, AN APOPTOTIC PROTEASE, NUCLEIC ACIDS ENCODING AND METHODS OF USE

This invention was made with government support under grants AI 35035-01 from the National Institutes of Health.

5 Accordingly, the government has certain rights to this invention.

Throughout this application various publications are referenced within parentheses. The disclosures of these publications in their entireties are hereby incorporated by 10 reference in this application in order to more fully describe the state of the art to which this invention pertains.

BACKGROUND OF THE INVENTION

The present invention relates generally to apoptosis 15 or, programed cell death, and more particularly, to a novel cysteine protease which can be used to modulate apoptosis for the therapeutic treatment of human diseases.

Apoptosis is a normal physiological process of cell 20 death that plays a critical role in the regulation of tissue homeostasis by ensuring that the rate of new cell accumulation produced by cell division is offset by a commensurate rate of cell loss due to death. It has now become clear that disturbances in apoptosis (also 25 referred to as physiological cell death or programmed cell death) that prevent or delay normal cell turnover can be just as important to the pathogenesis of diseases

as are known abnormalities in the regulation of proliferation and the cell cycle. Like cell division, which is controlled through complex interactions between cell cycle regulatory proteins, apoptosis is similarly 5 regulated under normal circumstances by the interaction of gene products that either induce or inhibit cell death.

The stimuli which regulate the function of these apoptotic gene products include both extracellular and 10 intracellular signals. Either the presence or the removal of a particular stimuli can be sufficient to evoke a positive or negative apoptotic signal. For example, physiological stimuli that prevent or inhibit apoptosis include, for example, growth factors, 15 extracellular matrix, CD40 ligand, viral gene products neutral amino acids, zinc, estrogen and androgens. In contrast, stimuli which promote apoptosis include growth factors such as tumor necrosis factor (TNF), Fas, and transforming growth factor β (TGF β), neurotransmitters, 20 growth factor withdrawal, loss of extracellular matrix attachment, intracellular calcium and glucocorticoids, for example. Other stimuli, including those of environmental and pathogenetic origins, also exist which can either induce or inhibit programmed cell death. 25 Although apoptosis is mediated by diverse signals and complex interactions of cellular gene products, the results of these interactions ultimately feed into a cell death pathway that is evolutionarily conserved between humans and invertebrates.

Several gene products which modulate the apoptotic process have now been identified. Although these products can in general be separated into two basic categories, gene products from each category can function 5 to inhibit or induce programmed cell death. One family of gene products are those which are members of the Bcl-2 family of proteins. Bcl-2, is the best characterized member of this family and inhibits apoptosis when overexpressed in cells. Other members of this gene 10 family include, for example, Bax, Bak, Bcl-x_L, Bcl-x_S, and Bad. While some of these proteins can prevent apoptosis others augment apoptosis (e.g. Bcl-x_L and Bak, respectively).

A second family of gene products, the interleukin-1-beta converting enzyme (ICE) family of proteases are related genetically to the *C. elegans* Ced-3 gene product which was initially shown to be required for programmed cell death in the roundworm, *C. elegans*. The ICE family of proteases includes human ICE, ICH-1_L, ICH-1_S, CPP32, 15 Mch2, ICH-2 and ICE_{rel} III. Among the common features of these gene products is that 1) they are cysteine proteases with specificity for substrate cleavage at Asp-x bonds, 2) they share a conserved pentapeptide sequence (QACRG) within the active site and 3) they are 20 synthesized as proenzymes that require proteolytic cleavage at specific aspartate residues for activation of protease activity. Cleavage of the proenzyme produces two polypeptide protease subunits of approximately 20kD (p20) and 10kD (p10) which, in the case of ICE, combine 25 non-covalently to form a tetramer comprised of two 30

p20:p10 heterodimers. Although these proteases, when expressed in cells, induce cell death, several alternative structural forms of these proteases, such as ICE δ , ICEe, ICH-1 α and Mch2 β , actually function to inhibit 5 apoptosis.

In addition to the Bcl-2 and Ced-3/ICE gene families which play a role in apoptosis in mammalian cells, it has become increasingly apparent that other gene products exist which are important in mammalian cell death and 10 which have yet to be identified. For example, in addition to Ced-3, another *C. elegans* gene known as Ced-4 exists which is also required for programmed cell death in *C. elegans*. However, mammalian homologues of this protein remain elusive and have not yet been identified. 15 Further, it is ambiguous as to whether other genes exist which belong to either of the above two apoptotic gene families or what role they may play in the programmed cell death pathway.

As stated previously, apoptosis plays an important 20 physiological role in maintaining tissue homeostasis. Programmed cell death functions in physiological processes such as embryonic development, immune cell regulation and normal cellular turnover. Therefore, the dysfunction, or loss of regulated apoptosis can lead to a 25 variety of pathological disease states. For example, the loss of apoptosis can lead to the pathological accumulation of self-reactive lymphocytes such as that occurring with many autoimmune diseases. Inappropriate loss of apoptosis can also lead to the accumulation of

virally infected cells and of hyperproliferative cells such as neoplastic or tumor cells. Similarly, the inappropriate activation of apoptosis can also contribute to a variety of pathological disease states including, 5 for example, acquired immunodeficiency syndrome (AIDS), neurodegenerative diseases and ischemic injury. Treatments which are specifically designed to modulate the apoptotic pathways in these and other pathological conditions can change the natural progression of many of 10 these diseases.

Thus, there exists a need to identify new apoptotic genes and their gene products and for methods of modulating this process for the therapeutic treatment of human diseases. The present invention satisfies this 15 need and provides related advantages as well.

SUMMARY OF THE INVENTION

The invention provides an isolated gene encoding Mch3, or functional fragment thereof. Also provided is an isolated nucleic acid sequence encoding Mch3 or 20 functional fragment thereof. The gene or nucleic acid sequence can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch3 nucleotide sequence. An isolated Mch3 polypeptide or functional fragment thereof is also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleotide and predicted amino acid sequence of the human Mch3 α (SEQ ID NOS:1 and 2) and Mch3 β (SEQ ID NOS:3 and 4), respectively. The nucleotide sequence of Mch3 β that is different from that of Mch3 α is shown below the nucleotide sequence of Mch3 α . The predicted amino acid sequence of Mch3 α is shown above the nucleotide sequence. The predicted amino acid sequence of Mch3 β that is different from that of Mch3 α is shown below the nucleotide sequence. Dotted lines indicate the spliced sequences in Mch3 α and β . The underlined Mch3 α nucleotide sequence is deleted in Mch3 β and is replaced by the intronic sequence shown below it. The putative active site pentapeptide of Mch3 α is boxed. The putative p20, p17 and p12 cleavage sites are indicated with a horizontal arrow. The vertical arrow indicates an intron location. Amino acid and nucleotide residues are numbered to the right of each sequence.

Figure 2 shows Sf9 cells that were infected with the following recombinant baculoviruses: column 1, AcNPV-Mch3 α -p17; column 2, AcNPV-Mch3 α -p12; column 3, AcNPV-Mch3 α -p17 and AcNPV-Mch3 α -p12; column 4, AcNPV-CPP32-p17; column 5, AcNPV-CPP32-p12; column 6, AcNPV-CPP32-p17 and AcNPV-CPP32-p12; column 7, AcNPV-MCH3 α -p17 and AcNPV-CPP32-p17; column 8, AcNPV-Mch3 α -p12 and AcNPV-CPP32-p12; column 9, AcNPV-Mch3 α -p17 and AcNPV-CPP32-p12; column 10, AcNPV-CPP32-p17 and AcNPV-Mch3 α -p12. 42 h postinfection, cells were examined microscopically and several fields were counted (average 1500 cells/condition) and the

number of apoptotic cells was expressed as a percentage of total cells counted.

Figure 3 shows the cleavage of ProMch3 α by CPP32.

(A) pbluescript vectors containing a GST-Mch3 α 2 or 5 a GST-CPP32 inserts under the T7 promoter were linearized with the appropriate restriction enzymes as indicated by arrows and then used as templates for in vitro transcription and translation in the presence of 35 S-methionine.

(B) Lanes 1 and 2; the GST-Mch3a2 DNA template was linearized with Eco RI before transcription/translation and the products of translation were incubated with buffer (lane 1) or CPP32 (lane 2) for 30 min at 30°C. Small amount of full length GST-Mch3a2 can be seen as a 15 64 kDa translation product (lane 1) or 35 kDa cleavage product due to incomplete digestion of the DNA template with Eco RI. Lanes 3-6, The GST-Mch3a2 DNA template was linearized with Xho I before transcription/translation and the products of translation were incubated for 30 min 20 on ice with buffer (lane 3) or at 30°C with buffer (lane 4), CPP32 (lane 5) or Mch3a (lane 6).

(C) The GST-CPP32 DNA template was linearized with Eco RI before transcription/translation and the products of translation were incubated for 30 min at 30°C with 25 buffer (lane 1), Mch3a (lane 2) or CPP32 (lane 3).

(D) The GST-Mch3a was immobilized on a GST-Sepharose resin and the resin-GST-Mch3a2 was incubated for 1h on ice with buffer (lane 1) or with CPP32 (lane 2) at 30°C. The protein products in B and C were analyzed 30 on a 14% SDS-gels and in D on a 10-20% gradient SDS-gels.

The arrows on the right of B and C indicate the cleavage products.

DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to a novel apoptotic cysteine protease termed Mch3. This protease is a member of the ICE family of cysteine protease which includes, for example, ICE, ICH-1_L, ICH-1_S, CPP32, Mch2, ICH-2 and ICE_{re}, III. Similar to other ICE related proteases, Mch3 is synthesized as a larger proenzyme and becomes active following proteolytic cleavage into two subunits of approximately 17kD (p17) and 12kD (p12). The two subunits form heterodimers which associate with each other into an active complex. Mch3 contains no known functionally significant sequence identities outside of the ICE family of cysteine proteases. Similar to these other cysteine proteases, substrate specificity uniquely requires an Asp residue in the P1 position of the substrate binding site with a small, preferably hydrophobic, residue in the P1' position. Overexpression of Mch3 protease results in the induction of apoptosis.

In one embodiment, the invention is directed to nucleic acids encoding the apoptotic cysteine protease Mch3. The nucleic acids are used to produce recombinant Mch3 protease, whose activity can be measured enzymatically. The recombinant Mch3 polypeptides are used to screen for Mch3 inhibitory compounds. Such pharmaceutical compounds are useful for the treatment or prevention of diseases which are characterized by

apoptotic cell death. Alternatively, the Mch3 polypeptides can be used to screen for pharmaceutical compounds which activate or act as agonists of Mch3 such as by inducing cleavage of the proenzyme into its active 5 subunits. Such compounds are useful for the treatment or prevention of diseases which are characterized by the loss of apoptotic cell death.

As used herein, the term "substantially" when referring to a Mch3 nucleotide or amino acid sequence is 10 intended to refer to the degree to which two sequences of between about 15-30 or more nucleotides in length, are identical or similar so as to be considered by those skilled in the art to be functionally equivalent. For example, the Mch3 nucleic acids of the invention have a 15 nucleotide sequence substantially the same as that shown in Figure 1 and in SEQ ID NOS: 1 and 3. Thus, if a second sequence is substantially the same as that shown in Figure 1 (SEQ ID NOS: 1 and 3), then it is considered functionally equivalent by those skilled in the art. 20 Methods for sequence comparisons and determinations of similarity are well known and routine within the art.

Functionally equivalent nucleic acid sequences include, for example, sequences that are related, but different and encode the same Mch3 polypeptide due to the 25 degeneracy of the genetic code as well as sequences that are related, but different and encode a different Mch3 polypeptide that exhibits similar functional activity. In both cases, the nucleic acids encode functionally equivalent gene products. Functional fragments of Mch3

encoding nucleic acids such as oligonucleotides, polyoligonucleotides, primers and the like are also considered to be within the definition of the term and the invention as claimed. Functional equivalency is also 5 relevant to Mch3 nucleic acids which do not encode gene products, for example, but instead are functional elements in and of themselves. Specific examples of such functional nucleic acids include, for example, promoters, enhancers and other gene expression regulatory elements.

10 Mch3 polypeptides of the invention have an amino acid sequence substantially similar to that shown in Figure 1 and in SEQ ID NOS:2 and 4. Functionally equivalent Mch3 amino acid sequences similarly includes, for example, related, but different sequences so long as 15 the different polypeptide exhibits at least one functional activity of Mch3. Such related, but different polypeptides include, for example, substitutions of conserved and non-essential amino acids. Fragments and functional domains of Mch3 are similarly included within 20 the definition of the term and the claimed invention.

Therefore, it is understood that limited modifications may be made without destroying the biological function of the Mch3 polypeptide and that only a portion of the entire primary structure may be required 25 in order to effect activity. For example, minor modifications of the Mch3 amino acid sequences (SEQ ID NOS: 2 and 4) which do not destroy their activity also fall within the definition of Mch3 and within the definition of the polypeptide claimed as such. Also, for

example, genetically engineered fragments of Mch3 either alone or fused to heterologous proteins such as fusion proteins, for example, that retain measurable enzymatic activity fall within the definition of the polypeptides 5 claimed as such. It is understood that minor modifications of primary amino acid sequence may result in polypeptides which have substantially equivalent or enhanced function as compared to the sequence set forth in Figure 1 (SEQ ID NOS 2 and 4). These modifications 10 may be deliberate, as through site-directed mutagenesis, or may be accidental such as through mutation in hosts which are Mch3 producers. All of these modifications are included as long as Mch3 biological function is retained. Further, various molecules can be attached to Mch3, for 15 example, other proteins, carbohydrates, lipids, or chemical moieties. Such modifications are included within the definition of Mch3 polypeptides.

The invention provides a gene encoding Mch3, or fragment thereof. The invention also provides an 20 isolated nucleic acid sequence encoding Mch3, or fragment thereof. The gene and nucleic acid sequences encode substantially the sequence as shown in SEQ ID NOS:1 and 3. Fragments of the gene or nucleic acid sequence are provided which comprise single or double stranded nucleic 25 acids having substantially the sequences shown in SEQ ID NOS:1 and 3.

The Mch3 nucleic acids of the present invention were identified and isolated by a novel approach of searching a human database of expressed sequence tags (ESTs) under

various stringencies to identify potential new sequence fragments which may have homology to the ICE family of cysteine proteases. Novel sequences identified as having potential homology to the ICE family of apoptotic 5 proteases can be used to design primers for attempting PCR amplification. The second primer is designed to encompass homologous regions in nucleic acid sequences that encode known ICE protease family members. In this specific case, the primer was directed to the GSWFI/GSWYI 10 pentapeptide sequence that is conserved in a number of the ICE/Ced-3 family of proteases. The primer design should take into account the predicted strandedness of both the EST sequence primer and the known primer. Thus, only if the homology search and hybridization conditions 15 are successfully determined, will such an approach allow PCR amplification of a fragment of the putative novel protease cDNA. As searching a genetic data base will yield homologous sequence matches to any query nucleotide sequence, additional criteria must be used to identify 20 the authentic ICE family homologue from among the non-specific homology matches. ICE family members share the highest degree of homology in the active site and catalytically important amino acid residues. A given EST returned by the search may not include one of these 25 highly homologous sites, but rather, may only include a region within the protease with cryptic homology. Confirming an EST as a novel ICE protease involves translation of all the positive EST hits in three different reading frames and subsequent identification of 30 conservative active site or catalytically important amino acid sequence motifs. Then, using conventional cDNA

cloning, a full length cDNA of the putative novel protease can be obtained and 1) analyzed for overall structural homology to ICE family members, 2) recombinantly expressed and analyzed for cysteine 5 protease activity, and 3) analyzed for the induction of programmed cell death by heterologous expression of the cDNA in appropriate cells.

Alternative methods than that described above for isolating Mch3 encoding nucleic acids can similarly be 10 employed. For example, using the teachings described herein, those skilled in the art can routinely isolate and manipulate Mch3 nucleic acids using methods well known in the art. All that is necessary is the sequence of the Mch3 encoding nucleic acids (Figure 1 and SEQ ID 15 NOS:1 and 3) or the Mch3 amino acid sequence (Figure 1 and SEQ ID NOS:2 and 4). Such methods include, for example, screening a cDNA or genomic library by using synthetic oligonucleotides, nucleic acid fragments or primers as hybridization probes. Alternatively, 20 antibodies to the Mch3 amino acid sequence or fragments thereof can be generated and used to screen an expression library to isolate Mch3 encoding nucleic acids. Other binding reagents to Mch3 polypeptides can similarly be used to isolate Mch3 polypeptides having substantially 25 the amino acid sequence show in Figure 1. Similarly, substrate reagents such as non-cleavable peptide analogues of cysteine proteases can be used to screen and isolate Mch3 polypeptides.

In addition, recombinant DNA methods currently used by those skilled in the art include the polymerase chain reaction (PCR) which, combined with the Mch3 nucleotide and amino acid sequences described herein, allows easy
5 reproduction of Mch3 encoding sequences. Desired sequences can be amplified exponentially starting from as little as a single gene copy by means of PCR. The PCR technology is the subject matter of United States Patent Nos. 4,683,195, 4,800,159, 4,754,065, and 4,683,202 all
10 of which are incorporated by reference herein.

The above described methods are known to those skilled in the art and are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1992) and the
15 various references cited therein and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (1989); and in Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1989). These references and the
20 publications cited therein are hereby expressly incorporated herein by reference.

The invention provides an isolated Mch3 polypeptide comprising substantially the amino acid sequence as that shown in Figure 1 (SEQ ID NOS:2 and 4). Mch3 functional
25 fragments are also provided. A specific example of an Mch3 functional fragment is the catalytic domain which contains the active site amino acid sequence QACRG.

Isolated Mch3 polypeptides of the invention can be obtained by a variety of methods known within the art. For example, the isolated peptides can be purified by biochemical methods including, for example, affinity chromatography. Affinity matrices which can be used for Mch3 isolation can be anti-Mch3 monoclonal or polyclonal antibodies prepared against the sequence shown in Figure 1 (SEQ ID NOS:2 and 4), or fragments thereof such as synthetic peptides. Alternatively, substrate analogues or enzymatic inhibitors of Mch3 can similarly be used as affinity matrices to isolate substantially pure Mch3 polypeptides of the invention.

Mch3 polypeptides can also be produced by recombinant methods known to those skilled in the art. Recombinant Mch3 polypeptides include, for example, an amino acid sequence substantially the same as that shown in Figure 1 (SEQ ID NOS:2 and 4) as well as fusion proteins and fragments thereof. The Mch3 encoding nucleic acids can be cloned into the appropriate vectors for propagation, manipulation and expression. Such vectors are known or can be constructed by those skilled in the art and should contain all expression elements necessary for the transcription, translation, regulation, and if desired, sorting of the Mch3 polypeptides. The vectors can also be for use in either prokaryotic or eucaryotic host systems so long as the expression and regulatory elements are of compatible origin. One of ordinary skill in the art will know which host systems are compatible with a particular vector. The recombinant

polypeptides produced can be isolated by the methods described above.

Apoptosis plays a significant role in numerous pathological conditions in that programmed cell death is either inhibited, resulting in increased cell survival, or enhanced which results in the loss of cell viability. Examples of pathological conditions resulting from increased cell survival include cancers such as lymphomas, carcinomas and hormone dependent tumors. Such hormone dependent tumors include, for example, breast, prostate and ovarian cancer. Autoimmune diseases such as systemic lupus erythematosus and immune-mediated glomerulonephritis as well as viral infections such as herpesvirus, poxvirus and adenovirus also result from increased cell survival or the inhibition of apoptosis.

In contrast, apoptotic diseases where enhanced programmed cell death is a prevalent cause generally includes, for example, degenerative disorders such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, and Cerebellar degeneration. Other diseases associated with increased apoptosis include, for example, myelodysplastic syndromes such as aplastic anemia and ischemic injury including myocardial infarction, stroke and reperfusion injury.

The Mch3 encoding nucleic acids and polypeptides of the invention can be used to diagnose, treat or reduce the severity of cell death mediated diseases such as those described above as well as other diseases mediated

by either increased or decreased programmed cell death. Additionally, the Mch3 encoding nucleic acids and polypeptides of the invention can be used to screen for pharmaceutical compounds and macromolecules which inhibit 5 or promote Mch3 mediated apoptosis.

For example, the Mch3 encoding nucleic acids, polypeptides and functional fragments thereof can be used to diagnose, or to generate reagents to diagnose diseases mediated or characterized by programmed cell death.

10 Diagnosis can be by nucleic acid probe hybridization with Mch3 containing nucleotide sequences, antibody or ligand mediated detection with Mch3 binding agents or by enzyme catalysis of detectable Mch3 substrates. Such methods are routine to those skilled in the art. Detection can
15 be performed ex vivo, for example, by removing a cell or tissue sample from an individual exhibiting or suspected of exhibiting a cell death mediated disease. Correlation of increased Mch3 expression or activity is indicative of diseases characterized by enhanced programmed cell death
20 whereas correlation of decreased Mch3 expression or activity is indicative of diseases characterized by the inhibition of programmed cell death.

The above Mch3 polypeptides can also be formulated into pharmaceutical compositions known within the art for 25 the treatment of cell death mediated diseases characterized by increased cell survival and proliferation. Functional fragments and peptides such as the catalytic domain of Mch3 can similarly be formulated for the treatment of such diseases associated with

increased cell survival and proliferation. Administration of Mch3 polypeptides and functional fragments thereof will induce apoptosis in treated cells and eliminate those cells characterized by increased cell 5 survival or proliferation. Administration of non-Mch3 polypeptides that do not directly act on Mch3 substrates but induce the activation of the Mch3 protease can similarly be used for the treatment of diseases characterized by increased cell survival and 10 proliferation.

To be effective, the Mch3 polypeptides must be introduced into the cells characterized by increased cell survival. Introduction can be accomplished by a variety of means known within the art including, for example, 15 lipid vesicles and receptor mediated endocytosis. Targeting to the appropriate cell type can similarly be accomplished through conjugation to specific receptor ligands, specific target cell antibodies and the like.

The Mch3 polypeptides are administered by 20 conventional methods, in dosages which are sufficient to induce apoptosis in the cells characterized by increased cell survival or proliferation. Such dosages are known or can be easily determined by those skilled in the art. Administration can be accomplished by, for example, 25 intravenous, interperitoneal or subcutaneous injection. Administration can be performed in a variety of different regimes which include single high dose administration or repeated small dose administration or a combination of both. The dosing will depend on the cell type,

progression of the disease and overall health of the individual and will be known or can be determined by those skilled in the art.

In contrast to the induction of Mch3 mediated apoptosis for the treatment of pathological conditions characterized by increased cell survival or proliferation, inhibitors of Mch3 can be used to treat diseases characterized by increased programmed cell death. Such inhibitors can be, for example, anti-Mch3 antibodies, proteins, or small peptidyl protease inhibitors which are formulated in a medium which allows introduction into the desired cell type. Alternatively, such inhibitors can be attached to targeting ligands for introduction by cell mediated endocytosis and other receptor mediated events. Specific examples of Mch3 peptidyl inhibitors are described in Table I of Example II and includes suicide inhibitors and substrate analogues such as the tetrapeptide DEVD aldehyde, YVAD aldehyde and the cowpox virus protein Crm A, for example.

Other inhibitors of Mch3 include, for example, small molecules and organic compounds which bind and inactivate Mch3 by a competitive or non-competitive type mechanism. Molecules or compounds which indirectly inhibit the Mch3 pathway can also be used as inhibitors of Mch3. Mch3 inhibitors can be identified by screening for molecules which demonstrate specific or beneficial Mch3 inhibitory activity. Such methods are described further below and can be practiced by those skilled in the art given the Mch3 nucleotide and amino acid sequences described herein.

Dominant/negative inhibitors of Mch3 can also be used to treat or reduce the severity of diseases characterized by increased programmed cell death. In this regard, Mch3 β polypeptides which lack the active site QACRG (SEQ ID NO:4) can be used to bind p12 subunits of Mch3 and prevent active tetrameric complexes from forming. The mechanism of Mch3 β dominant inhibition of Mch3 α is indicated to be similar to the dominant negative inhibition of Ich-1 α by Ich-1 β . Subunits from other ICE related cysteine proteases can similarly be used as dominant/negative inhibitors of Mch3 activity and therefore treat diseases mediated by programmed cell death. Such subunits should be selected so that they bind either the p17 or p12 Mch3 polypeptides and prevent their assembly into active tetrameric protease complexes. Moreover, Mch3 subunits which have been modified so as to be catalytically inactive can also be used as dominant negative inhibitors of Mch3. Such modifications include, for example, mutation of the active site cysteine residue to include but not limited to Alanine or glycine.

Mch3 substrate antagonists can similarly be used to treat or reduce the severity of diseases mediated by increased programmed cell death. Such substrate antagonists can bind to and inhibit cleavage by Mch3. Inhibition of substrate cleavage prevents commitment progression of programmed cell death. Substrate antagonists include, for example, ligands and small molecule compounds.

Treatment or reduction of the severity of cell death mediated diseases can also be accomplished by introducing expressible nucleic acids encoding Mch3 polypeptides or functional fragments thereof into cells characterized by 5 such diseases. For example, elevated synthesis rates of Mch3 can be achieved by , for example, using recombinant expression vectors and gene transfer technology. Such methods are well known within the art and will be described below with reference to recombinant viral 10 vectors. Other vectors compatible with the appropriate targeted cell can accomplish the same goal and therefore can be substituted in the methods described herein in place of recombinant viral vectors.

Recombinant viral vectors are useful for *in vivo* 15 expression of a desired nucleic acid because they offer advantages such as lateral infection and targeting specificity. Lateral infection is inherent in the lifecycle of, for example, retroviruses and is the process by which a single infected cell produces many 20 progeny virions that bud off and infect neighboring cells. The result is a large area becomes rapidly infected, most of which were not initially infected by the original viral particles. This is in contrast to vertical-type of infection in which the infectious agent 25 spreads only through daughter progeny. Viral vectors can also be produced that are unable to spread laterally. This characteristic can be useful if the desired purpose is to introduce a specified gene into only a localized number of targeted cells.

Typically, viruses infect and propagate in specific cell types. Therefore, the targeting specificity of viral vectors utilizes this natural specificity to in turn specifically introduce a desired gene into

5 predetermined cell types. The vector to be used in the methods of the invention will depend on desired cell type to be targeted. For example, if neurodegenerative diseases are to be treated by decreasing the Mch3 activity of affected neuronal cells then a vector

10 specific for cells of the neuronal cell lineage should be used. Likewise, if diseases or pathological conditions of the hematopoietic system are to be treated, than a viral vector that is specific for blood cells and their precursors, preferably for the specific type of

15 hematopoietic cell, should be used. Moreover, such vectors can additionally be modified with specific receptors or ligands and the like to modify or alter target specificity through receptor mediated events. These modification procedures can be performed by, for

20 example, recombinant DNA techniques or synthetic chemistry procedures. The specific type of vector will depend upon the intended application. The actual vectors are also known and readily available within the art or can be constructed by one skilled in the art using well

25 known methodology.

Viral vectors encoding Mch3 nucleic acids or inhibitors of Mch3 can be administered in several ways to obtain expression of such sequences and therefore either increase or decrease the activity of Mch3 in the cells

30 affected by the disease or pathological condition. If

viral vectors are used, for example, the procedure can take advantage of their target specificity and consequently, do not have to be administered locally at the diseased site. However, local administration can

5 provide a quicker and more effective treatment.

Administration can also be performed by, for example, intravenous or subcutaneous injection into the subject. Injection of the viral vectors into the spinal fluid can also be used as a mode of administration, especially in

10 the case of neurodegenerative diseases. Following injection, the viral vectors will circulate until they recognize host cells with the appropriate target specificity for infection.

As described above, one mode of administration of

15 Mch3 encoding vectors can be by direct inoculation locally at the site of the disease or pathological condition. Local administration is advantageous because there is no dilution effect and therefore a smaller dose is required to achieve Mch3 expression in a majority of

20 the targeted cells. Additionally, local inoculation can alleviate the targeting requirement required with other forms of administration since a vector can be used that infects all cells in the inoculated area. If expression is desired in only a specific subset of cells within the

25 inoculated area then promoter and expression elements that are specific for the desired subset can be used to accomplish this goal. Such non-targeting vectors can be, for example, viral vectors, viral genomes, plasmids, phagemids and the like. Transfection vehicles such as

30 liposomes can be used to introduce the non-viral vectors

described above into recipient cells within the inoculated area. Such transfection vehicles are known by one skilled within the art. Alternatively, however, non-targeting vectors can be administered directly into a 5 tissue of any individual. Such methods are known within the art and are described by, for example, Wolff et al. (Science 247:1465-1468 (1990)).

Additional features can be added to the vectors to ensure safety and/or enhance therapeutic efficacy. Such 10 features include, for example, markers that can be used to negatively select against cells infected with the recombinant virus. An example of such a negative selection marker is the TK gene described above that confers sensitivity to the antibiotic gancyclovir. 15 Negative selection is therefore a means by which infection can be controlled because it provides inducible suicide through the addition of antibiotic. Such protection ensures that if, for example, mutations arise that produce mutant forms of Mch3, dysfunction of 20 apoptosis will not occur.

As described previously, the Mch3 encoding nucleic acids and Mch3 polypeptides of the invention can be used to screen for compounds which inhibit or enhance the expression of Mch3 protease activity. Such screening 25 methods are known to those skilled in the art and can be performed by either *in vitro* or *in vivo* procedures. For example, described in Example II is a specific *in vitro* assay for Mch3 activity. This assay employs Mch3 polypeptide expressed in an active, processed form

recombinantly in *E. coli*, whose protease activity is measured by incubation with a fluorescent substrate (DEVD-AMC). Also described therein are peptide and polypeptide inhibitors of Mch3. This assay can be used 5 to screen synthetic or naturally occurring compound libraries, including macromolecules, for agents which either inhibit or enhance Mch3 activity. The Mch3 polypeptides to be used in the assay can be obtained by, for example, *in vitro* translation, recombinant expression 10 or biochemical procedures. Methods other than that described in Example II can also be used to screen and identify compounds which inhibit Mch3. A specific example is phage display peptide libraries where greater than 10^6 peptide sequences can be screened in a single 15 round of panning. Such methods as well as others are known within the art and can be utilized to identify compounds which inhibit or enhance Mch3 activity.

It is understood that modifications which do not substantially affect the activity of the various 20 embodiments of this invention are also included within the definition of the invention provided herein. Accordingly, the following examples are intended to illustrate but not limit the present invention.

EXAMPLE I

25

Cloning And Characterization of Mch3

This Example shows the cloning, sequence analysis and tissue distribution of Mch3. The results described

herein indicate that Mch3 is a novel member of the ICE family of cysteine proteases.

To identify potentially novel members of the ICE family of cysteine proteases, an approach combining 5 information from the GenBank database of human expressed sequence tags (ESTs) and PCR was employed. Initially, Ced-3/ICE-like apoptotic cysteine proteases from Jurkat T-lymphocytes were enriched by amplification of a human Jurkat cDNA library using degenerate PCR primers encoding 10 the conserved GSWFI/GSWYI pentapeptides (Fernandes-Alnermi et al., Cancer Res. 55:2737-2742 (1995)). This amino acid sequence has been found to be conserved among ICE family members. Briefly, a 10 μ l aliquot of human Jurkat λ Uni-ZapTM XR cDNA library containing 15 approximately 10^8 pfu was denatured at 99°C for 5 min. and used as a substrate for PCR amplification with a degenerate primer encoding the pentapeptide GSWFI/GSWYI and a T3 vector-specific primer (Stratagene).

The enriched library was then amplified with a 20 primer derived from an EST sequence (T50828) identified in a homology search of the GenBank database using a query nucleotide sequence corresponding to the CPP32 cDNA sequence minus the untranslated nucleotides (e.g. CPP32 coding sequence). This secondary amplification was 25 performed starting with a 10 μ l aliquot of the above amplified sequences combined with a primer derived from the GenBank sequence T50828 (primer T50-pr1: CCGTGGAATAGGCGAAGAG, SEQ ID NO: 5) and a second vector specific primer (SK-Zap: CAGGAATTGGCACGAG, SEQ ID NO:

6). The secondary amplification products were cloned into a Sma I cut pBluescript II KS' vector. All clones were screened by PCR using a degenerate oligonucleotide corresponding to the conserved active site amino acid sequence QACRG and the SK-Zap primer. Clones that were positive for the presence of the QACRG coding sequence were then subjected to DNA sequencing using T3 and T7 sequencing primers (Stratagene). This amplification and screen resulted in the identification of a Ced-3/ICE-like partial cDNA with high homology to CPP32 and Ced-3. The partial cDNA was then excised from the vector, radiolabeled and used to screen the original Jurkat λ Uni-Zap™ XR cDNA library. Positive λ clones were purified, rescued into the pBluescript II SK plasmid vector and sequenced.

The second screen of the Jurkat λ Uni-Zap™ XR cDNA library resulted in the isolation of several cDNA clones. One cDNA, named Mch3, contains an open reading frame of 909 bp that encodes a 303 amino acid protein with a predicted molecular mass of approximately 34 kD (Figure 1 and SEQ ID NOS: 1 and 2). The initiator methionine at nucleotide 44 conforms to the consensus Kozak translation initiation sequence (20). A second cDNA clone named Mch3β (SEQ ID NO: 3) was also identified and found to contain a deletion and insertion corresponding to nucleotides 488-592 (amino acids 149-183) of the Mch3α sequence (Fig. 1) (SEQ ID NO: 1). Mch3β also has a longer 5' nontranslated sequence.

Exon/Intron analysis of the Mch3 genomic region that correspond to the deletion/insertion in Mch3 β revealed that Mch3 β mRNA resulted from two simultaneous alternative splicing events. The first event caused the 5 deletion of nucleotides 488-592 of the Mch3 α sequence (SEQ ID NO: 1) due to the use of an alternative splice donor located within the coding region of the 5' exon and an alternative splice acceptor located within the 3' intron. The second splicing event caused an insertion of 10 74 bp intronic sequence due to the use of an alternative splice donor located within the intron and the normal splice acceptor of the 3' exon. All the alternative splice donor/acceptor sites used in these events conform to the GT/AG rule. As a result of the deletion and 15 insertion, Mch3 β cDNA did not maintain the same reading frame as Mch3 α after amino acid 148. The new reading frame in Mch3 β does not encode a QACRG pentapeptide sequence and it terminates with a TGA stop codon corresponding to bp 837-839 of Mch3 β (Fig. 1; SEQ ID NO: 20 1). Mch3 β encodes a protein of 253 amino acids with a predicted molecular mass of ~28 kDa (SEQ ID NO: 4).

In vitro translated Mch3 α and Mch3 β migrate as 36 and 33 kDa protein products. The smaller translation products seen in the Mch3 α and Mch3 β translation 25 reactions are probably internally translated products. Although the calculated molecular mass of Mch3 β is ~28 kDa, its migration as a 33 kDa indicates posttranslational modification such as phosphorylation. This result is evident from the high number of serine 30 residues in Mch3 β sequence that is different from Mch3 α .

and its migration in SDS gels as a fuzzy band rather than a sharp distinct band. The function and activity of Mch3 α is discussed further below. However, similar to the alternatively spliced Ich-1 isoform (Ich-1s), (Wang et al., Cell 78:739-750 (1994)) Mch3 β is thought to be a negative regulator of apoptosis and could inhibit the activity of the parental enzyme by acting as a dominant inhibitor.

Sequence comparison of the predicted full length

10 Mch3 α protein sequence shows the highest homology to human CPP32 and Mch2 α and the *C. elegans* CED-3 protein. (Fernandes-Alnemri et al., J. Biol. Chem. 269:30761-30764 (1994)). Overall, Mch3 α protein shares ~53% identity (67% similarity) with CPP32, ~35% identity (56% similarity) with Mch2 α and ~33% identity (55% similarity) with CED-3. Mch3 α shows less than 30% identity with other family members such as ICE, NEDD/ICH-1, Tx (ICH-2, ICE_{reI}-II) or ICE_{reI}III. In addition to the conservation of the active site QACRG pentapeptide the predicted

15 structure of Mch3 α appears to be similar to CPP32. CPP32 is cleaved at Asp28 and Asp175 to generate two polypeptides of molecular masses of 17 kDa (p17) and 12 kDa (p12) that form the active CPP32 enzyme complex. Based on the high homology between Mch3 α and CPP32, it is

20 likely that the cleavage sites in Mch3 α are Asp53 and Asp 198 (Figure 1). Cleavage at these sites would generate two polypeptides equivalent to the p17 and p12 subunits of CPP32. However, there are three potential aspartic acid cleavage sites at positions 15, 20 and 23 that could

25 be used to remove a short propeptide during processing of

Mch3 α to the active enzyme. In fact, the tetrapeptide DSVD (amino acids 20-23 of Mch3 α) is very similar to the DEVD tetrapeptide substrate of CPP32. This result indicates that the Mch3 α is a substrate for CPP32. In 5 addition, three Asp cleavage sites (Asp193, Asp204 and Asp206) located between the two subunits may serve as potential processing sites to separate the two subunits.

To determine if Mch3 exhibits apoptotic activity, we investigated whether this gene product induces early 10 apoptosis in Sf9 baculovirus cells. Briefly, Sf9 cells were infected with recombinant baculoviruses encoding full length Mch3 α , full length CPP32, or truncated Mch3 α or CPP32 variants, separately or in various combinations. Cells were then examined microscopically for 15 morphological signs of apoptosis such as blebbing of the cytoplasmic membrane, condensation of nuclear chromatin and release of small apoptotic bodies. In addition the genomic DNA was examined for internucleosomal DNA cleavage.

20 For the construction of transfer vectors and recombinant baculoviruses, the Mch3 cDNA was amplified by PCR using primers T50-pr3 GCCATAAACTCTCCTCACTT (SEQ ID NO: 7) and T50-pr4 ATGGCAGATGATCAGGGC (SEQ ID NO: 8) and subcloned into the pBluescript II SK⁺ vector. The Mch3 25 sequence was then excised with Bam HI and subcloned into a Bam HI cut pVL1393 (Invitrogen, San Diego, California) to generate the pVL-Mch3 α transfer vector. The cDNA encoding the p20 and p12 subunits of Mch3 were amplified with PCR using the following primers (p20 subunit; T50-

pr4 (SEQ ID NO: 8) and Mch3-p20-TAG-CTAGTCGGCCTGGATGCCATC (SEQ ID NO: 9) and p12 subunit; Mch3-p12-ATG ATGTCGGGGCCCATCAATGAC (SEQ ID NO: 10)) and T50-pr9 GACCCATTGCTTCTCAGC (SEQ ID NO: 11)). The PCR products 5 were then cloned into a Sma I cut pVL1393 to generate pVL-Mch3-p20 and pVL-Mch3-p12 transfer vectors. The recombinant transfer vectors were then used to generate recombinant Baculoviruses as previously described (Summers et al., "Manual of Methods for Baculovirus 10 Vectors and Insert Culture Procedures," Texas Experimental Station Bulletin No. 1555 (Texas A&M University, College Station, Texas (1987); and Alnemri et al., J. Biol. Chem. 266:3925-3936 (1991)).

For the induction of apoptosis in Sf9 cells by Mch3 α 15 and CPP32. Internucleosomal DNA cleavage was assessed as a characteristic marker. Briefly, total cellular DNA was isolated at 42 h postinfection from Sf9 cells infected with the wild type baculovirus or the recombinant baculoviruses AcNPV-Mch3 α or AcNPV-ICE, which have been 20 described previously (Summers et al. and Alnemri et al. *supra*). The DNA samples were analyzed by electrophoresis in a 1.8% agarose gel containing ethidium bromide.

Expression of full length Mch3 α in Sf9 cells caused approximately 50% of the cells to undergo apoptosis by 48 25 h postinfection which was also manifested by induction of internucleosomal DNA cleavage. This result is consistent with Mch3 being an apoptotic protease since ICE, CPP32 and Mch2 α yield similar results. On the other hand, truncated Mch3 α (amino acids 1-198) that encodes only the

p20 subunit or truncated Mch3 α (amino acids 199-303) that encodes only the p12 subunit, were unable to induce apoptosis in Sf9 cells when expressed separately (Figure 2, columns 1 and 2). However, when these two subunits 5 were coexpressed, ~49% of the cells died by apoptosis (column 3). Similarly, the two subunits of CPP32 were not apoptotic when expressed separately (columns 4 and 5) but were apoptotic when coexpressed together (column 6). The most interesting results were obtained when Mch3-p20 10 subunit was coexpressed with CPP32-p12 subunit or vice versa (i.e. CPP32-p20 with Mch3-p12). These combinations were able to cause apoptosis in more than 50% of the cells (columns 9 and 10). No significant induction of apoptosis was observed in control cells coexpressing 15 Mch3-p20 and CPP32-p20 together or cells coexpressing Mch3-p12 and CPP32-p12 together (columns 7 and 8). These data indicate that Mch3 α and CPP32 can heterodimerize in vivo in eucaryotic cells to form active apoptotic complexes. Such a dimerization now increases the 20 complexity of the apoptotic response in mammalian cells. One interesting observation so far is that all known mammalian Ced3/ICE-like cysteine proteases are expressed in a single cell line namely human Jurkat T-lymphocytes. The ability of different members of the ICE-family such 25 as Mch3 and CPP32 or ICE and Tx to heterodimerize indicates that there may be some overlap in function or subtle differences in specifications that have yet to be characterized.

To further characterize Mch3, the tissue
30 distribution was analyzed by Northern blot analysis of

poly A+ RNA isolated from different human tissues. The analysis was performed on Northern blots prepared by Clontech containing 2 µg/lane of poly A+ RNA.

Radioactive riboprobe of Mch3α was prepared using a Sma I 5 linearized pBluescript II SK-Mch3α as a substrate for T7 RNA polymerase in the presence of [α^{32} P] UTP. The blot was hybridized, washed and then visualized by autoradiography. The results indicate a major 2.4 Kb Mch3 message was detectable in all tissues examined. The 10 lowest expression of Mch3 mRNA was seen in whole brain. Examination of Mch3 mRNA in different regions of the brain also showed low but detectable expression. Similar tissue distribution was also seen with CPP32 mRNA, although the CPP32 message is more abundant than Mch3 15 message in brain tissues. The size of Mch3 mRNA was consistent with the length of the cloned Mch3α and β cDNAs (Fig.1; SEQ ID NOS: 1 and 3). Two less abundant messages of (0.8 and 3.3 Kb) were also detectable in some tissues such as the small intestine. The larger message 20 could be an incompletely processed Mch3 RNA or an alternatively spliced Mch3 isoform. The smaller message could be a degradation product or an alternatively spliced Mch3 isoform.

The enzymatic activity of Mch3α was also 25 characterized in vitro. Mch3 was expressed in *E. coli* as a fusion protein with glutathione S-transferase (GST) as described for Mch2α, ICE and CPP32 (See for example, Alnemri et al., *J. Biol. Chem.* 270:4312-4317 (1995)). Two GST-Mch3α expression vectors were constructed and 30 transformed into DH5α bacteria. The Mch3α1 cDNAs were

subcloned in-frame into the Bam HI site of the bacterial expression vector pGEX-2T (Pharmacia, Biotech, Inc.). The first construct (Mch3 α 1) contains a PCR generated cDNA that encodes amino acids 1-303 of Mch3 α fused to the 5 C-terminus of GST. The second construct (Mch3 α 2) contains a Bam HI fragment derived from the Mch3 λ library clone that encodes the full length Mch3 α and an extra 16 amino acids derived from the 5' nontranslated region fused to the C-terminus of GST. After induction 10 with IPTG, bacterial extracts were prepared from *E. coli* expressing the recombinant fusion proteins. The extracts were adsorbed to glutathione-Sepharose resin, washed several times and then analyzed by SDS-PAGE.

The Mch3 α 1 preparation contained a major GST-fusion 15 protein that migrated as a ~30 kDa band. On the other hand, the Mch3 α 2 preparation contains a major GST-fusion protein that migrated as a ~32 kDa band. The GST nonfusion protein control migrated as a ~28 kDa protein. These results are consistent with autocatalytic 20 processing and cleavage of GST-Mch3 α in bacteria most probably at Asp23 of Mch3 α to generate the 30 and 32 kDa GST-prodomain fusion. A minor GST-fusion protein that migrated as a 33 kDa band in Mch3 α 1 preparation and as a 35 kDa protein in Mch3 α 2 preparation was also seen above 25 the major 30 and 32 kDa bands, respectively. These two bands are intermediate cleavage products generated by cleavage at a site C-terminal to Asp23 of Mch3 α . This indicates that the final product of Mch3 α processing is cleaved at an Asp site C-terminal to Asp23 and is likely 30 to be Asp53.

EXAMPLE II**Kinetic Properties and Enzymatic Activity of Mch3 α**

This Example characterizes the protease activity and substrate specificity of the apoptotic cysteine protease 5 Mch3.

The kinetic properties of the bacterially expressed recombinant Mch3 α and CPP32 were determined using the tetrapeptide substrate DEVD-AMC in a continuous fluorometric assay. The DEVD-AMC substrate is the 10 poly(ADP-ribose)polymerase (PARP) cleavage site P1-P4 tetrapeptide (Nicholson et al., *Nature* 376:37-43 (1995)). Briefly, activity of Mch3 α and CPP32 was measured using bacterial lysates in ICE buffer (25 mM HEPES, 1 mM EDTA, 5mM DTT, 0.1% CHAPS, 10% sucrose, pH 7.5) at room 15 temperature (24-25°C). K_i's were determined from the hydrolysis rate of 50 μ M DEVDamc (10 μ M for CPP32) in ICE buffer following a 30 min preincubation of the enzyme with inhibitor. Prior to incubation with enzyme, purified crmA was activated by incubation with 5 mM DTT 20 for 10 min at 37°C.

TABLE I

Parameter	Protease	
	Mch3	CPP32
k_{cat}/K_m (DEVDamc, mM ⁻¹ s ⁻¹)	11	1600
K_m (DEVDamc, μ M)	51	13
k_{cat}/K_m (YVADamc, mM ⁻¹ s ⁻¹)	NA	0.067
K_m (YVADamc, μ M)	NA	>500
K_i (DEVDaldehyde, nM)	1.8	0.59
K_i (YVADaldehyde, μ M)	>10	8.5
K_i (CrmA, μ M)	>1	0.56

10 Both Mch3 α and CPP32 exhibited a Michaelis-Menton kinetics in cleaving this substrate with K_m values of 51 and 13 μ M, respectively (Table I). These K_m values and other kinetic parameters are shown above in Table I. For example, the K_m value of recombinant CPP32 (13 μ M) was
 15 comparable to the K_m value of purified human CPP32 ($9.7 \pm 1.0 \mu$ M) reported recently (Nicholson et al., *supra*). The peptide aldehyde DEVD-CHO was also a potent inhibitor of both Mch3 α and CPP32 at low nM concentrations ($K_{iMch3}=1.8$ nM and $K_{iCPP32}=0.59$ nM). In contrast, the ICE
 20 inhibitor peptide aldehyde YVAD-CHO ($K_{iICE}=0.76$ nM) was a very weak inhibitor of both Mch3 α and CPP32 ($K_{iMch3}>10$ μ M and $K_{iCPP32}=8.5$ μ M). The ICE inhibitor cowpox serpin, Crm A, similarly was also a very weak inhibitor of Mch3 α and CPP32 ($K_{iMch3}>1\mu$ M and $K_{iCPP32}=0.56$ μ M). These data indicate
 25 that the two enzymes, Mch3 α and CPP32 have similar substrate specificity.

In addition, the high concentration of Crm A required to inhibit either CPP32 or Mch3 indicates that the target of Crm A inhibition in apoptosis is unlikely

to be CPP32 or Mch3 α . Therefore, Crm A inhibition of apoptosis is likely mediated through ICE or an ICE-related protease and not through Mch3 or CPP32. CPP32 has also been recently reported to be the PARP cleaving enzyme in apoptosis (Nicholson et al., *supra*, and Tewari et al., Cell 81:1-9 (1995)). However, since our data indicate that Mch3 α has a similar substrate specificity towards PARP as CPP32 it is possible that some of this previously reported activity is due to Mch3 α . For example, incubation of purified bovine PARP or human HeLa nuclei with Mch3 α resulted in a complete cleavage of PARP in less than 15 min. A similar activity was also observed with CPP32 and with S/M extracts derived from chicken DU249 cells committed to apoptosis.

Inhibition studies with the serine proteases TLCK and TPCK (N-Tosyl-L- Lysyl chloromethylketone and N-Tosyl-L-phenylalanyl chloromethylketone, respectfully) revealed interesting results. At 1 mM DTT concentration TPCK was able to inhibit both Mch3 α and CPP32 PARP cleaving activity. At the same DTT concentration TLCK did not inhibit Mch3 α but it did inhibit CPP32 activity. In contrast, at 5 mM DTT concentration both TLCK and TPCK were unable to inhibit either Mch3 α or CPP32 activity. These results indicate that the concentration of thiol agents influences significantly the activity of cysteine protease and their sensitivity to some inhibitors such as TLCK and TPCK.

EXAMPLE IIIINTERRELATIONSHIP OF MCH3 α AND CPP32

This Example shows that Mch3 α is a substrate for CPP32.

5 The ability of subunits derived from Mch3 α to form active complexes with subunits derived from CPP32 raised the possibility that Mch3 α was a substrate for CPP32 and vice versa. To test this possibility, a GST-Mch3 α and GST-CPP32 fusion proteins were *in vitro* translated in
10 reticulocyte lysate in the presence of 35 S-methionine. Briefly, Mch3 α , Mch3 β , GST-Mch3 α and GST-CPP32 cDNAs were subcloned into the pBluescript II KS plasmid under the T7 promoter. These vectors were linearized with the appropriate restriction enzyme and used as template for
15 T7 RNA polymerase. The *in vitro* synthesized mRNA was then used for *in vitro* translation with reticulocyte lysates as described previously (Alnemri et al., *supra*).

To assess substrate specificity of these proteases, the labeled lysates were incubated with recombinant
20 active CPP32 or Mch3 α enzymes (equal DEVD-AMC cleaving activity). After the Incubation period, the cleavage products were immobilized on GST-sepharose, washed several times and analyzed by SDS-PAGE and autoradiography. Schematic diagrams of the vectors are shown in Figure 3A. The results of the cleavage products indicate that incubation of CPP32 with the *in vitro* translated GST-Mch3 α generated a GST-prodomain cleavage product of molecular mass 32 kDa (Figure 3B, Lane 5).

This band was similar in size and comigrated with the bacterially expressed GST-prodomain. Although Mch3 α exhibited significantly less activity than CPP32 towards the *in vitro* translated GST-Mch3 α , a similar cleavage product was observed (Figure 3B, lane 6). The intermediate 36 kDa minor GST-prodomain cleavage product was also seen in this reaction. No cleavage was observed when CPP32 was incubated with an *in vitro* translated GST control or when the *in vitro* translated GST-Mch3 α was 10 incubated with buffer (Figure 3B, lanes 2-4).

The same experiment was performed with *in vitro* translated GST-CPP32 (Figure 3C). In this case, CPP32 showed a very weak activity towards its precursor and generated a faint GST-prodomain band of 30 kDa size as 15 expected from cleavage at Asp28 (lane 3). No cleavage was observed in the buffer control or the Mch3 α reaction (Figure 3C, lanes 1 and 2). Although Mch3 α or CPP32 can autoactivate/autoprocess when overexpressed in bacteria, such a process is likely to be regulated in mammalian 20 cells. Therefore, the ability of CPP32 to cleave the Mch3 α precursor better than Mch3 α itself and the weak activity of CPP32 or Mch3 α towards the CPP32 precursor indicates that Mch3 α precursor is down stream of CPP32 and that CPP32 is likely dependent on an upstream 25 protease for activation *in vivo*.

In light of the fact that CPP32 was observed to efficiently cleave the GST-Mch3 α precursor, a further purification of the cleavage products from the GST-prodomain was performed and analyzed. Briefly, the 35 S-

labeled GST-Mch3 α precursor was immobilized on GST-sepharose and washed several times. The resine-GST-Mch3 α precursor was incubated with active CPP32 and the soluble products cleaved from the immobilized GST-Mch3 α precursor were then analyzed on a 10-20% gradient SDS gel and visualized by autoradiography (Fig. 3D). The three bands that migrate as 17-19 kDa proteins represent the large subunit of Mch3 at different stages of processing. Similarly, the two bands of 12-13 kDa size represent the small subunit of Mch3 α . The bands that migrate as 30 and 35 kDa proteins represent Mch3 α precursor minus the prodomain.

In conclusion, the Mch3 gene encodes two Mch3 proteins, an active Mch3 α and a Mch3 β splice variant with an undetermined activity. Because of the high degree of homology between Mch3 and CPP32 and their ability to heterodimerize to form active heteromeric complexes, the Mch3 β variant is likely to function as a dominant inhibitor of both Mch3 β and CPP32. The similarity between CPP32 and Mch3 α in terms of their kinetic properties and their substrate specificity towards the DEVD peptide and PARP indicates that CPP32 may not be the sole PARP cleaving enzyme in apoptosis. The possibility that Mch3 α is down stream of CPP32 suggest that CPP32 might be the PARP cleaving enzyme during the early stages of apoptosis but that Mch3 α may be involved in the final stages of PARP cleavage and apoptosis. It therefore appears that activation of the death program in mammalian cells is regulated by multiple pathways and that

execution of apoptosis may involve different cascades of cysteine proteases.

Example IV

Identification of Mch3 Inhibitors

5 This Example describes the identification of Mch3 α inhibitors from a library of synthetic organic compounds.

In order to identify compounds useful for modulating apoptosis, a library of compounds was screened for Mch3 α inhibitory activity. Briefly, Mch3 α was expressed in
10 bacteria as described in Example II to yield a active protease. The activity of the recombinant protease was similarly assayed as described in Example II. This assay was used for the screening and identification of inhibitors of Mch3 α from a library of greater than 300
15 synthetic compounds. The screening resulted in the identification of greater than 10 compounds having potent inhibitory activity ($IC_{50} \leq 100$ nM). The structure of one such identified inhibitor is benzyloxycarbonyl-Asp-Glu-Val-Asp-Aldehyde which exhibits an IC_{50} of 4.0 nM.

20 Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various
25 modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

What is claimed is:

1. An isolated gene encoding Mch3, or functional fragment thereof.
2. The isolated gene of claim 1, comprising substantially the coding sequence in SEQ ID NOS:1 or 3.
3. The isolated gene of claim 1, wherein said functional fragment comprises single or double stranded nucleic acids of the sequence shown in SEQ ID NOS:1 or 3.
4. The isolated gene of claim 1, wherein said wherein said functional fragment comprises coding or non-coding strands of the sequence shown in SEQ ID NOS:1 or 3.
- 15 5. An isolated nucleic acid sequence encoding Mch3, comprising substantially the sequence shown in SEQ ID NOS:1 or 3, or functional fragment thereof.
6. The isolated nucleic acid sequence of claim 3, wherein said functional fragment comprises single or double stranded nucleic acids of the sequence shown 20 in SEQ ID NOS:1 or 3.

7. The isolated nucleic acid sequence of claim 3,
wherein said functional fragment comprises coding or
non-coding strands of the sequence shown in SEQ ID
NOS:1 or 3.

5 8. An isolated Mch3 polypeptide, comprising
substantially the amino acid sequence shown in SEQ
ID NOS: 2 and 4, or functional fragment thereof.

9. The isolated Mch3 polypeptide of claim 8,
wherein said functional fragment further comprises
10 the catalytic domain of the protease.

FIGURE 1

FIGURE 2





FIGURE 3



INTERNATIONAL SEARCH REPORT

Inte onal Application No.
PCT/US 96/18118

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/52 C12N9/64 C07K16/40												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
A	<p>J. BIOL CHEM., vol. 269, no. 49, 9 December 1994, pages 30761-30764, XP000616157</p> <p>T. FERNANDES-ALNEMRI ET AL.: "CPP32, a novel human apoptotic protein with homology to <i>Caenorhabditis elegans</i> cell death protein Ced-3 and mammalian Interleukin-1beta-converting enzyme." cited in the application see the whole document</p> <p>---</p> <p>-/-</p>											
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.										
* Special categories of cited documents : <table> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier document but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
2	Date of the actual completion of the international search 17 April 1997	Date of mailing of the international search report 25.04.97										
Name and mailing address of the ISA European Patent Office, P.B. 3818 Patentlaan 2 NL - 2280 Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer Van der Schaaf, C										

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 96/18118

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CELL, vol. 81, 2 June 1995, pages 801-809, XP002013933 M. SEWARI ET AL.: "Yama/CPP32beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase." see the whole document</p> <p>---</p>	
A	<p>NATURE, vol. 376, 6 July 1995. pages 37-43, XP000574812 D.W. NICHOLSON ET AL.: "Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis." cited in the application see the whole document</p> <p>---</p>	
P,X	<p>WO 96 13603 A (HUMAN GENOME SCIENCES INC ;HE WEI WU (US); ROSEN CRAIG A (US); HUD) 9 May 1996 see the whole document</p> <p>---</p>	1-9
P,X	<p>CANCER RESEARCH 55 (24). 1995. 6045-6052. ISSN: 0008-5472, 15 December 1995, XP000614740 FERNANDES-ALNEMRI T ET AL: "Mch3, a novel human apoptotic cysteine protease highly related to CPP32." see the whole document</p> <p>---</p>	1-9
P,X	<p>BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 225 (3). 1996. 983-989. ISSN: 0006-291X, XP000616158 TISO N ET AL: "Chromosomal localization of the human genes, CPP32, Mch2, Mch3, and Ich-1, involved in cellular apoptosis." see the whole document</p> <p>---</p>	1-9
P,X	<p>JOURNAL OF BIOLOGICAL CHEMISTRY 271 (4). 1996. 1825-1828. ISSN: 0021-9258, 26 January 1996, XP000616154 LIPPKE J A ET AL: "Identification and characterization of CPP32- Mch2 homolog 1, a novel cysteine protease similar to CPP32." see the whole document</p> <p>---</p>	1-9
2		-/-

INTERNATIONAL SEARCH REPORT

Int'l. Search Application No

PCT/US 96/18118

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	J. BIOL. CHEM. (1996), 271(3), 1621-5 CODEN: JBCHA3;ISSN: 0021-9258, 19 January 1996, XP000616150 DUAN, HANGJUN ET AL: "ICE - LAP3, a novel mammalian homolog of the <i>Caenorhabditis</i> <i>elegans</i> cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis" see the whole document ---	1-9
P,A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 93 (11). 1996. 5437-5442. ISSN: 0027-8424, 28 May 1996, XP000616168 PAI J-T ET AL: "Purification and cDNA cloning of a second apoptosis-related cysteine protease that cleaves and activates sterol regulatory element binding proteins." see the whole document ---	1-9
P,A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, no. 15, 23 July 1996, pages 7464-7469, XP000616167 FERNANDES-ALNEMRI T ET AL: "IN VITRO ACTIVATION OF CPP32 AND MCH3 BY MCH4, A NOVEL HUMAN APOPTOTIC CYSTEINE PROTEASE CONTAINING TWO FADD-LIKE DOMAINS" -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No

PCT/US 96/18118

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9613603 A	09-05-96	AU 2768895 A	23-05-96